S1226 Sarcopenia Is a Risk Factor for Post-TIPS Hepatic Encephalopathy and Mortality: A Systematic Review and Meta-Analysis

Ahmed, Zohaib; Badal, Joyce; Nawaz, Ahmad; Arif, Syeda F.; Farooq, Umer; Kamal, Faisal; Javaid, Toseed; Aziz, Muhammad; Renno, Anas; Lee‐Smith, Wade; Mahmood, Asif; Nawras, Ali; Hassan, Mona

doi:10.14309/01.ajg.0000861544.70951.2c

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В настоящий момент нет убедительных данных для рекомендации какого-либо из гипоаммониемических препаратов в качестве монотерапии для первичной профилактики явной ПЭ после наложения трансъюгулярного внутрипеченочного портосистемного шунта; возможно, эффективной окажется комбинированная терапия [105,106].…”

Section: как влияет гипоаммониемическая терапия на исходы пэ у пациен...unclassified

Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement)

Nadinskaia,

Maevskaya,

Bakulin

et al. 2024

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

Introduction. In cirrhotic patients, hyperammonemia develops due to impaired ammonia detoxification and portosystemic blood shunting and is most commonly associated with hepatic encephalopathy and sarcopenia. Currently, there are questions regarding the diagnosis of hyperammonemia and the effect of ammonia-lowering therapy on disease outcomes.Materials and methods. The Russian Scientific Liver Society selected a panel of seven experts in liver cirrhosis research and management of patients with this disease to make reasoned statements and recommendations on the issue of diagnostic and prognostic value of hyperammonemia in patients with liver cirrhosis, hepatic encephalopathy and sarcopenia.Results. The Delphi panel identified the most relevant topics, in the form of PICO questions (patient or population, intervention, comparison, outcome). The Delphi panel made six questions relevant to clinical practice and gave reasoned answers, framed as ‘clinical practice recommendations and statements’ with evidence-based comments. The questions and statements were based on the search and critical analysis of medical literature by keywords in Englishand Russian-language databases. The formulated questions could be combined into four categories: hepatic encephalopathy, sarcopenia, hyperammonemia, and ammonia-lowering therapy.Conclusions. The results of the experts' work are directly relevant to the quality management of patients with liver cirrhosis, and their recommendations and statements can be used in clinical practice.

show abstract

Section: как влияет гипоаммониемическая терапия на исходы пэ у пациен...unclassified

Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement)

Nadinskaia,

Maevskaya,

Bakulin

et al. 2024

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

show abstract

S1226 Sarcopenia Is a Risk Factor for Post-TIPS Hepatic Encephalopathy and Mortality: A Systematic Review and Meta-Analysis

Cited by 1 publication

References 0 publications

Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement)

Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement)

Contact Info

Product

Resources

About